Patents by Inventor Stephen T. Gately

Stephen T. Gately has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Autophagy inhibitors
    Patent number: 10544100
    Abstract: The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: January 28, 2020
    Assignees: Translational Genomics Research Institute, Van Andel Research Institute
    Inventors: Jeffrey Paul MacKeigan, Katie Renee Martin, Megan Lynne Goodall, Stephen T. Gately, Tong Wang
  • Autophagy Inhibitors
    Publication number: 20180290980
    Abstract: The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors.
    Type: Application
    Filed: June 8, 2018
    Publication date: October 11, 2018
    Inventors: Jeffrey Paul MacKeigan, Katie Renee Martin, Megan Lynne Goodall, Stephen T. Gately, Tong Wang
  • Therapeutic combination for cancer treatment
    Patent number: 9532984
    Abstract: This invention relates to a synergistic pharmaceutical combination of glucose lowering drugs and autophagy inhibitors, kits containing such combinations, and methods of using such combinations to treat subjects suffering from cancers carrying a specific KRAS mutation. This invention also relates to a theranostic method for cancer treatment.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: January 3, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: Stephen T. Gately
  • Solid forms of curcumin
    Patent number: 9447050
    Abstract: The present invention provides forms of curcumin and the pharmaceutical compositions thereof. The forms of curcumin disclosed herein are curcumin polymorph Form III, curcumin-2-aminobenzimidazole co-crystal, and curcumin-L-lysine co-crystal. Further, the invention provides methods inhibiting cancer cells and HSV-1 using these curcumin novel solid forms.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: September 20, 2016
    Assignees: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, VAN ANDEL RESEARCH INSTITUTE
    Inventors: Stephen T. Gately, Steven J. Triezenberg, Tong Wang
  • Autophagy Inhibitors
    Publication number: 20160137607
    Abstract: The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors.
    Type: Application
    Filed: November 19, 2015
    Publication date: May 19, 2016
    Inventors: Jeffrey Paul MacKeigan, Katie Renee Martin, Megan Lynne Goodall, Stephen T. Gately, Tong Wang
  • THERAPEUTIC COMBINATION FOR CANCER TREATMENT
    Publication number: 20140113930
    Abstract: This invention relates to a synergistic pharmaceutical combination of glucose lowering drugs and autophagy inhibitors, kits containing such combinations, and methods of using such combinations to treat subjects suffering from cancers carrying a specific KRAS mutation. This invention also relates to a theranostic method for cancer treatment.
    Type: Application
    Filed: June 11, 2012
    Publication date: April 24, 2014
    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventor: Stephen T. Gately
  • Solid Forms of Curcumin
    Publication number: 20140031403
    Abstract: The present invention provides forms of curcumin and the pharmaceutical compositions thereof. The forms of curcumin disclosed herein are curcumin polymorph Form III, curcumin-2-aminobenzimidazole co-crystal, and curcumin-L-lysine co-crystal. Further, the invention provides methods inhibiting cancer cells and HSV-1 using these curcumin novel solid forms.
    Type: Application
    Filed: April 5, 2012
    Publication date: January 30, 2014
    Applicants: VAN ANDEL RESEARCH INSTITUTE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Stephen T. Gately, Steven J. Triezenberg, Tong Wang
  • Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
    Patent number: 6916800
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: July 12, 2005
    Assignee: Pfizer Inc
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
    Patent number: 6858598
    Abstract: A method of using an MMP inhibitor and optionally radiation therapy, and one or more antineoplastic agents of the topoisomerase class selected from the group consisting of irinotecan and topotecan, as a combination therapy for the treatment of neoplasia is disclosed.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: February 22, 2005
    Assignee: G. D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
    Patent number: 6833373
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: December 21, 2004
    Assignee: G.D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
    Publication number: 20040234624
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.
    Type: Application
    Filed: June 10, 2004
    Publication date: November 25, 2004
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
    Patent number: 6689787
    Abstract: The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: February 10, 2004
    Assignee: G. D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Methods and compositions for generating angiostatin
    Patent number: 6576609
    Abstract: The invention provides a method of treating a neoplastic disease in a human by administering a therapeutically effective amount of plasminogen activator effective to increase the amount of angiostatin present in the human to treat the disease. The invention also provides a method of treating a neoplastic disease in a human by administering a therapeutically effective amount of plasminogen activator and sulfhydryl donor effective to increase the amount of angiostatin present in the human to treat said disease.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: June 10, 2003
    Assignee: Northwestern University
    Inventors: Gerald Soff, Stephen T. Gately, Przemyslaw Twardowski
  • Antiangiogenic combination therapy for the treatment of cancer
    Publication number: 20020103141
    Abstract: The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.
    Type: Application
    Filed: April 25, 2001
    Publication date: August 1, 2002
    Inventors: John P. McKearn, Gary B. Gordon, James Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Methods and compositions for generating angiostatin
    Patent number: 5801012
    Abstract: The invention provides a method of generating angiostatin in vitro comprising contacting plasminogen or plasmin with a plasminogen activator and a sulfhydryl donor.
    Type: Grant
    Filed: September 17, 1996
    Date of Patent: September 1, 1998
    Assignee: Northwestern University
    Inventors: Gerald Soff, Stephen T. Gately, Przemyslaw Twardowski